Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

DNA methylation entropy is a biomarker for aging

Chan J, Rubbi L, Pellegrini M. DNA methylation entropy is a biomarker for aging. Aging (Albany NY). 2025 Mar 12;17. doi: 10.18632/aging.206220. Epub ahead of[...]

Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States

Sisk BA, Eng W, Aye J, Mack J, Tran A, Ogino J, Pearson E, Bies J, Smink G, Shah SD, Mohney L, Fassel H, Schulte[...]

Augmented Intelligence and Dermatology – Part II: Bias, Benchmarks, Guidelines, Ethics, Regulation, and Future Directions

Dovigi E, Wongvibulsin S, Lee I, Novoa R, Cai Z, Rotemberg V, Daneshjou R. Augmented Intelligence and Dermatology - Part II: Bias, Benchmarks, Guidelines, Ethics,[...]